WIN-Partners Co., Ltd. AI Stock Analysis
Want to see JP:3183 full AI Analyst Report?
WIN-Partners Co., Ltd. (3183) AI Stock Analysis
WIN-Partners Co., Ltd.
(TSE/TYO:3183)
WIN-Partners earns a moderate score built on financial stability rather than growth firepower. The company's near debt-free balance sheet, steadily compounding revenue and growing equity base provide genuine defensive appeal, but razor-thin net margins of around 2.4%, mid-single-digit ROE and a history of volatile — at times negative — free cash flow cap the upside. Valuation is supportive, with a low P/E of 13.7 and an above-average 4.23% dividend yield offering income-oriented investors a reasonable entry point. The main drag is technical: negative MACD, a weak RSI of 34 and a share price still below its 200-day average suggest the market has yet to regain conviction, although the stock is holding above its shorter-term moving averages. Overall, this is a low-beta, income-tilted holding suited to investors prioritising stability over returns.
WIN-Partners Co., Ltd. (3183) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 33.38B
- Dividend Yield
- 4.45%
- Average Volume (3M)
- 30.37K
- Price to Earnings (P/E)
- 13.4
- Beta (1Y)
- 0.51
- Revenue Growth
- 13.99%
- EPS Growth
- 17.93%
- Country
- Japan
- Employees
- 653
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
WIN-Partners Co., Ltd. Business Overview & Revenue Model
Company Description
Established in 1973 and headquartered in Tokyo, Japan, WIN-Partners Co., Ltd. leverages its subsidiaries to distribute a comprehensive range of medical devices to healthcare institutions, primarily across Japan. Its diverse product offerings include...
WIN-Partners Co., Ltd. Financial Statement Overview
Summary
A solid but unspectacular financial profile. The balance sheet is the standout strength (score 75): essentially debt-free through FY2025 with only a negligible debt-to-equity ratio (~0.03) projected for FY2026, steadily rising equity (¥21.1B to ¥24.1B), and a conservative equity-to-asset ratio of 46-52%. The income statement (score 58) shows dependable revenue growth from ¥62.1B in FY2021 to ¥81.4B in FY2025 with ¥90.4B projected for FY2026 (~7.7% growth), but profitability is thin and slowly compressing — net margins of just 2.4-2.9% and EBIT margins down from ~4.0% to ~3.3%. Cash flow (score 55) is the weakest link, with volatile operating cash flow (¥445M in FY2023 vs. ¥3.0B in FY2024) and negative free cash flow in FY2022 and FY2023, though conversion is improving with ¥2.7B of free cash flow projected for FY2026. ROE of 7-9% is adequate rather than compelling.
Income Statement
58NeutralBalance Sheet
75PositiveCash Flow
55Neutral| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 98.25B | 90.39B | 81.41B | 77.06B | 70.85B | 62.12B |
| Gross Profit | 11.64B | 10.66B | 9.89B | 9.53B | 8.66B | 7.74B |
| EBITDA | 3.94B | 3.32B | 3.10B | 2.92B | 3.11B | 2.45B |
| Net Income | 2.50B | 2.12B | 2.02B | 1.84B | 2.05B | 1.54B |
Balance Sheet | ||||||
| Total Assets | 51.90B | 50.63B | 46.65B | 47.75B | 43.91B | 40.21B |
| Cash, Cash Equivalents and Short-Term Investments | 14.27B | 15.93B | 16.21B | 18.16B | 16.77B | 17.12B |
| Total Debt | 0 | 713.06M | 0 | 0 | 0 | 0 |
| Total Liabilities | 28.71B | 27.34B | 22.58B | 24.37B | 21.12B | 19.07B |
| Stockholders Equity | 23.20B | 23.29B | 24.07B | 23.39B | 22.78B | 21.14B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 2.70B | 1.59B | 2.54B | -525.17M | 673.91M |
| Operating Cash Flow | 0 | 2.93B | 2.06B | 3.04B | 445.15M | 1.85B |
| Investing Cash Flow | 0 | -132.31M | -2.17B | -219.47M | 1.92B | -1.28B |
| Financing Cash Flow | 0 | -3.08B | -1.83B | -1.45B | -1.16B | -947.37M |
WIN-Partners Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3183, the sentiment is Negative. The current price of 1214.00 is below the 20-day moving average (MA) of 1233.10, below the 50-day MA of 1243.80, and below the 200-day MA of 1281.95, indicating a bearish trend. The MACD of -2.79 indicates Positive momentum. The RSI at 44.02 is Neutral, neither overbought nor oversold. The STOCH value of 9.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:3183.
WIN-Partners Co., Ltd. Peers Comparison
Overall Rating
JP:318362Neutral
JP:448058Neutral
JP:707150Neutral
JP:706149Neutral
JP:760045Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 62Neutral | JPY 34.85B | 13.38 | ― | 4.45% | 13.99% | 17.93% | |
| 58Neutral | JPY 56.61B | 32.49 | 11.30% | ― | 21.01% | 10.15% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | JPY 25.66B | 20.00 | ― | 1.53% | 1.93% | -65.20% | |
| 49Neutral | JPY 2.86B | -28.15 | ― | ― | 6.75% | -119.69% | |
| 45Neutral | JPY 6.87B | -4.42 | ― | 6.51% | -8.68% | -75.03% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:3183 | WIN-Partners Co., Ltd. | 1214.00 | -41.30 | -3.29% | |
| JP:4480 | Medley, Inc. | 1780.00 | -870.00 | -32.83% | |
| JP:7061 | Japan Hospice Holdings Inc. | 337.00 | -944.94 | -73.71% | |
| JP:7071 | Amvis Holdings.Inc. | 261.00 | -172.57 | -39.80% | |
| JP:7600 | Japan Medical Dynamic Marketing, Inc. | 261.00 | -205.88 | -44.10% |
WIN-Partners Co., Ltd. Corporate Events
WIN-Partners Reports Strong First-Half Sales and Profit Growth
WIN-Partners Co., Ltd. reported strong consolidated results for the six months ended September 30, 2026, with net sales rising 18.0% year on year to ¥51.6 billion, operating profit increasing 40.9% to ¥2.1 billion, and profit attributable to owners o...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026